Shots:

• Ligand to receive upfront- milestones- and royalties for each of the product developed using OmniAb technology. Genagon to get WW rights for Ligand’s Omniab technology including the developed products OmniRat- OmniMouse- OmniFlic & OmniChicken and will fund the future development programs
• The focus of the agreement is to develop immune-oncology therapies based on Ligand’s OmniAb technology for targeting pathways in immune cells
• Ligand ‘s OmniAb technology is a three-species platform with four technologies used for producing mono- and bispecific human therapeutic Abs

Ref: Ligand | Image: Fortune